PDGF-BB Tendon Healing Composition for Strength Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tendinopathies, such as tendinosis and tendinitis, offer limited long-term benefits and fail to effectively enhance tendon healing and strength, particularly in conditions like Achilles tendon ruptures, where degenerative changes lead to reduced tensile strength and increased re-rupture rates.
Innovation Solution
Administration of a composition comprising platelet-derived growth factor (PDGF), specifically PDGF-BB, in combination with a buffer, directly to the affected tendon site to promote tendon healing by enhancing cellular proliferation, angiogenesis, and extracellular matrix production, thereby improving tendon strength and recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for tendinopathies are used, then treatment simplicity is maintained, but tendon healing effectiveness and long-term benefits are limited
Solution Approach 1:
The patent employs a composite treatment composition containing PDGF-BB protein, heparin, and a buffering agent. This composite formulation synergistically combines growth factor activity (PDGF-BB) with enhanced stability and sustained release properties (heparin), while the buffering agent maintains physiological pH. The composite nature of this composition directly addresses the contradiction by providing superior tendon healing effectiveness through multiple mechanisms while maintaining treatment simplicity through a single injectable formulation.
2Productivity
If PDGF composition is administered to promote rapid tendon healing, then tendon strength recovery speed is improved, but treatment cost and complexity increase
Solution Approach 1:
The patent utilizes PDGF-BB, a growth factor that is naturally present at injury sites but in insufficient quantities. By administering a concentrated composition of PDGF-BB preliminarily at the time of injury or during the early healing phase, the treatment accelerates the natural healing process before scar tissue formation occurs. This preliminary action principle enables rapid tendon strength recovery (achieving up to 90% of final strength within 7 days) without requiring complex multi-stage treatment protocols.
Solution Approach 2:
Heparin serves as an intermediary molecule in this treatment composition. It binds to PDGF-BB, protecting it from degradation and extending its half-life in the bloodstream and at the injury site. This intermediary relationship between heparin and PDGF-BB enables sustained release of the growth factor, maintaining therapeutic levels over time without requiring repeated complex administrations, thus achieving rapid and sustained tendon healing.
3Reliability
If conventional tendon repair methods are used, then treatment simplicity is maintained, but re-rupture risk increases due to reduced tensile strength
Solution Approach 1:
The patent fundamentally changes the biochemical parameters of the tendon healing environment by introducing exogenous PDGF-BB. This growth factor alters the cellular response to injury by stimulating tenocyte proliferation, collagen synthesis, and angiogenesis. The parameter change in growth factor concentration and activity directly increases tendon tensile strength during the critical healing phase, reducing re-rupture risk while maintaining treatment simplicity through a single injectable composition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method results in a significant increase in tendon strength, with up to 90% of final strength achieved within 7 days, and sustained recovery, reducing the risk of re-rupture and improving clinical outcomes compared to existing treatments.
Implementation Method 1
enhancing cellular proliferation, angiogenesis, and extracellular matrix production
Implementation Method 2
enhancing cellular proliferation, angiogenesis, and extracellular matrix production
Implementation Method 3
enhancing cellular proliferation, angiogenesis, and extracellular matrix production
Data Source
AI summary
Provided herein are compositions and methods for the treatment of tendinopathies, such as tenosynovitis, tendinosis or tendinitis, including Achilles tendinopathy, patellar tendinopathy, lateral epicondylitis or “tennis elbow,” medial epicondylitis or “golfer's elbow,” plantar fasciitis, and rotator cuff tendinopathy, and in particular to methods for the treatment of tendinopathies by administering compositions comprising platelet-derived growth factor (PDGF).